Payment overview · 2025
General Payments
$484.88
24 reported records · 15 companies
Healthcare provider profile · identity verified
Dheeraj Kumar Bobba, MD
Allopathic & Osteopathic Physicians|Hospitalist · MESA, AZ · NPI 1588878508
Verified facts
What the public records show
CMS Open Payments records show Dheeraj Kumar Bobba, MD received $484.88 in general payments during 2025 across 24 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 15.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $72.56 | 15.0% | 4 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $57.88 | 11.9% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $53.90 | 11.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $52.91 | 10.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $40.39 | 8.3% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $28.53 | 5.9% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $24.10 | 5.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.53 | 4.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.65 | 4.5% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $19.92 | 4.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $18.80 | 3.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.55 | 3.8% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $18.33 | 3.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.95 | 3.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.88 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $484.88 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $72.56 | 4 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $57.88 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $53.90 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $52.91 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $40.39 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $28.53 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $18.80 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
121 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 513 | 174 |
| Levothyroxine Sodium | Levothyroxine Sodium | 305 | 87 |
| Gabapentin | Gabapentin | 290 | 102 |
| Eliquis | Apixaban | 266 | 62 |
| Furosemide | Furosemide | 226 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 172 | 71 |
| Losartan Potassium | Losartan Potassium | 163 | 64 |
| Sertraline Hcl | Sertraline Hcl | 139 | 48 |
| Metformin Hcl | Metformin Hcl | 137 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 59 |
| Trazodone Hcl | Trazodone Hcl | 131 | 49 |
| Lisinopril | Lisinopril | 130 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 123 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 55 |
| Ozempic | Semaglutide | 121 | 21 |
| Potassium Chloride | Potassium Chloride | 120 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 119 | 52 |
| Carvedilol | Carvedilol | 106 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 90 | 35 |
| Levetiracetam | Levetiracetam | 85 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 41 |
| Ondansetron Hcl | Ondansetron Hcl | 74 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 20 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 66 | 33 |
| Jardiance | Empagliflozin | 61 | 18 |
| Montelukast Sodium | Montelukast Sodium | 58 | 16 |
| Donepezil Hcl | Donepezil Hcl | 56 | 17 |
| Midodrine Hcl | Midodrine Hcl | 54 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 20 |
| Nifedipine Er | Nifedipine | 52 | 18 |
| Xarelto | Rivaroxaban | 51 | 17 |
| Mirtazapine | Mirtazapine | 50 | 23 |
| Baclofen | Baclofen | 47 | 23 |
| Lactulose | Lactulose | 47 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 15 |
| Cefdinir | Cefdinir | 45 | 41 |
| Omeprazole | Omeprazole | 45 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | 14 |
| Prednisone | Prednisone | 41 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 40 | 19 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Allopurinol | Allopurinol | 38 | 14 |
| Simvastatin | Simvastatin | 38 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 19 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 37 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | 13 |
| Divalproex Sodium | Divalproex Sodium | 36 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 23 |
| Synthroid | Levothyroxine Sodium | 35 | 11 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 21 |
| Tramadol Hcl | Tramadol Hcl | 34 | 23 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 33 | 16 |
| Latanoprost | Latanoprost | 33 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 30 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | 12 |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 29 | 28 |
| Alendronate Sodium | Alendronate Sodium | 28 | 11 |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Glipizide | Glipizide | 28 | 12 |
| Lurasidone Hcl | Lurasidone Hcl | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | 17 |
| Finasteride | Finasteride | 26 | suppressed |
| Budesonide | Budesonide | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 24 | suppressed |
| Calcitriol | Calcitriol | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 23 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | 17 |
| Meropenem | Meropenem | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | 14 |
| Cefepime Hcl | Cefepime Hcl | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | 12 |
| Glipizide Er | Glipizide | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 19 |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 19 | 11 |
| Famotidine | Famotidine | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 17 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Daptomycin | Daptomycin | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | 12 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | 13 |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Genotropin | Somatropin | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $484.88 · 24 records | Otsuka America Pharmaceutical, Inc. | AFREZZA, AUSTEDO XR, CAPLYTA, FREESTYLE LIBRE 3, INJECTAFER, KISUNLA, Korlym, Omnipod, REXULTI, UNITHROID, Vest Therapy Und, Wegovy, YUPELRI, ZENPEP | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error